Illumina, Inc. $ILMN Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2,880.0% in the first quarter, Holdings Channel reports. The fund owned 42,375 shares of the life sciences company’s stock after purchasing an additional 40,953 shares during the period. Fifth Third Bancorp’s holdings in Illumina were worth $5,223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Candriam S.C.A. purchased a new stake in Illumina in the 1st quarter valued at approximately $12,533,000. Sequoia Financial Advisors LLC boosted its position in Illumina by 19.6% during the first quarter. Sequoia Financial Advisors LLC now owns 8,128 shares of the life sciences company’s stock worth $1,002,000 after purchasing an additional 1,331 shares in the last quarter. Whipplewood Advisors LLC boosted its position in Illumina by 7,287.5% during the first quarter. Whipplewood Advisors LLC now owns 591 shares of the life sciences company’s stock worth $73,000 after purchasing an additional 583 shares in the last quarter. Kestra Advisory Services LLC grew its holdings in Illumina by 13.5% in the first quarter. Kestra Advisory Services LLC now owns 4,209 shares of the life sciences company’s stock valued at $519,000 after purchasing an additional 501 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. grew its holdings in Illumina by 3.4% in the first quarter. Resona Asset Management Co. Ltd. now owns 45,162 shares of the life sciences company’s stock valued at $5,551,000 after purchasing an additional 1,485 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $186.65 on Friday. The firm’s 50 day moving average is $166.44 and its two-hundred day moving average is $143.34. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $28.24 billion, a P/E ratio of 33.94, a PEG ratio of 3.56 and a beta of 1.47. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $196.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $0.97 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ILMN. Citigroup upped their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Piper Sandler upped their target price on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday. Finally, Royal Bank Of Canada assumed coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $156.88.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider directly owned 20,953 shares of the company’s stock, valued at $3,771,540. This trade represents a 2.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by company insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.